The document discusses submission documents for regulators like DMFs, CTDs, and eCTDs. It provides details on the contents required for a Drug Master File submission to the FDA, including transmittal letters, administrative information, and specifics on the five types of DMFs. Type I covers manufacturing facilities and procedures, Type II covers drug substances and products, Type III packaging materials, Type IV excipients, and Type V is for reference information accepted by the FDA. Guidance is provided on environmental assessments and stability studies to include.
Objectives , policies and principles of cGMP guidelines in pharmaceutical ind...JaskiranKaur72
The presentation contains detailed information about the current GMP in the pharmaceutical industry. It has objectives , policies and principles of cGMP guidelines.
Pdf file is being attached in the link below- https://drive.google.com/file/d/11al8n8AqrkUR_Vnm-z4Mp6O0elzyniEz/view?usp=drivesdk
As the audit proceeds, there might arise some situations where the facts indicate there is a failure, either partially or wholly, of the quality management system, such a situation is called nonconformity/ deficiencies”.
What is IPQC & IPQC Test
Appearance
Drug content determination
pH
Sensitivity test
Spreadability
Rate of absorption
Extrudability
Consistency Test
Rheology & Viscosity
In this slide contains definition, validation plan, types of Qualification of Dry Powder Mixture.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).RIPER, anantapur
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
Role of quality system and audits in pharmamaceuticalganpat420
Introduction
cGMP Regulations
Quality Assurance Function
Quality Systems Approach
Management Responsibilities
Resources
Manufacturing Operations
Evaluation Activities
Transitioning to Quality Systems Approach
Audit Checklist for Drug Industry
Objectives , policies and principles of cGMP guidelines in pharmaceutical ind...JaskiranKaur72
The presentation contains detailed information about the current GMP in the pharmaceutical industry. It has objectives , policies and principles of cGMP guidelines.
Pdf file is being attached in the link below- https://drive.google.com/file/d/11al8n8AqrkUR_Vnm-z4Mp6O0elzyniEz/view?usp=drivesdk
As the audit proceeds, there might arise some situations where the facts indicate there is a failure, either partially or wholly, of the quality management system, such a situation is called nonconformity/ deficiencies”.
What is IPQC & IPQC Test
Appearance
Drug content determination
pH
Sensitivity test
Spreadability
Rate of absorption
Extrudability
Consistency Test
Rheology & Viscosity
In this slide contains definition, validation plan, types of Qualification of Dry Powder Mixture.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).RIPER, anantapur
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
Role of quality system and audits in pharmamaceuticalganpat420
Introduction
cGMP Regulations
Quality Assurance Function
Quality Systems Approach
Management Responsibilities
Resources
Manufacturing Operations
Evaluation Activities
Transitioning to Quality Systems Approach
Audit Checklist for Drug Industry
A Drug Master File (DMF) is a confidential submission to the FDA containing detailed information about the manufacturing, processing, packaging, and storing of a pharmaceutical product. It is submitted by a drug manufacturer to support a regulatory application, such as a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA), without disclosing the information to the applicant. The DMF system helps streamline the regulatory review process while protecting proprietary information.
This presentation gives an overview of the Drug Master File, a document submitted by the company or pharmaceutical industry to the regulatory authorities. It indicates that the company's product meets the desired quality standards. A brief introduction followed by types of DMF, its reviewing procedure and applications may give you a better understanding about Drug Master File.
DRUG MASTER FILE
Presented by :
RUSHIKESH D MENDHE
Roll no - 511
Mpharm Ist Year
(Department of Pharmaceutics)
Content : :
INTRODUCTION
TYPES OF DMF
DMF FORMAT & ASSEMBLY
DELIVERY OF DMF TO FDA
SUBMISSION OF DMF
THE MECHANISM OF A DRUG MASTER FILE
CTD & ELECTRONIC DMFS
UPDATES TO DMF
CLOSURE OF A DRUG MASTER FILE
APPLICATION OF DMF
REFERENCE
INTRODUCTION :
A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.
This guideline does not impose mandatory requirements.
Objectives :
Main Objective of the DMF is to support regulatory requirements
To prove the quality, safety and efficacy of the medicinal product
TYPES OF DMF :
DMF FORMAT & ASSEMBLY :
The DMF is submitted as Original and Duplicate jackets, collated, assembled, paginated, and jacketed, using covers obtained from the government printing office and a respecifically provided for the DMFs
Multiple volumes are numbered, and the paper must be standard paper size
Paper length should not be less than 10 inches nor more than 12 inches.
Each volume of a DMF should be not more than 2 inches thick
DELIVERY OF DMF TO FDA :
DMF should be submitted at following address :
Food and Drug Administration Center for Drug Evaluation and Research Central Document Room 5901 – B Ammendale Road Beltsville, MARYLAND 20705-1266 USA
SUBMISSION OF DMF :
The DMF must be submitted in two copies, one with a blue cover and one with a red cover.
Each page of each copy of the DMF should be dated and consecutively numbered.
Each DMF submission should contain :
• A Transmittal letter
• Administrative information about the submission
• Other specific information
A. Transmittal Letter :
i) Original Submissions :
• Identification of submission: Original, the type of DMF as classified in Section III, and its subject.
• Identification of the applications, if known, that the DMF is intended to support, including the name and address of each sponsor, applicant, or holder, and all relevant document numbers.
• Signature of the holder or the authorized representative.
• Typewritten name and title of the signer.
ii) Ammendments :
• Identification of submission: Amendment, the DMF number, type of DMF, and the subject of the amendment.
• A description of the purpose of submission, e.g., update, revised formula, or revised process.
• Signature of the holder or the authorized representative.
• Typewritten name and title of the signer.
B. Administrative information about the submission:
Introduction
Automation in pharmaceutical industry
Classification of industrial & laboratory automation
Advantages
Disadvantages
Process automation in tablet production
Example of material handling improvement
Processing step elimination or combination
Rotary tablet press
Tableting improvements
Questions
References
Autoclave
Principle of Autoclave
Construction of Autoclave
Working of Autoclave
Qualification of Autoclave
Installation Qualification
Operational Qualification
Performance Qualification
References
Qualification of Tablet Compression Machine.pptxDhruvi50
Tablet Compression Machine
Principle of Tablet Compression Machine
Construction of Tablet Compression Machine
Working of Tablet Compression Machine
Qualification of Tablet Compression Machine
Installation Qualification
Operational Qualification
Performance Qualification
References
Tray Dryer
Principle of Tray Dryer
Construction of Tray Dryer
Working of Tray Dryer
Qualification of Tray Dryer
Installation Qualification
Operational Qualification
Performance Qualification
References
Fluidized Bed Dryer
Principle of FBD
Construction of FBD
Working of FBD
Steps of Fluidization
Qualification of FBD
Design Qualification
Installation Qualification
Operational Qualification
Performance Qualification
References
Energy Resources
Conventional Energy Resources
Fossil fuels
Nuclear energy
Hydroelectric energy
Non-conventional Energy Resources
Wind energy
Bio-fuel
Solar energy
Tidal energy
Energy Resources
Conventional Energy Resources
Fossil fuels
Nuclear energy
Hydroelectric energy
Non-conventional Energy Resources
Wind energy
Bio-fuel
Solar energy
Tidal energy
Energy Resources
Conventional Energy Resources
Fossil fuels
Nuclear energy
Hydroelectric energy
Non-conventional Energy Resources
Wind energy
Bio-fuel
Solar energy
Tidal energy
Energy Resources
Conventional Energy Resources
Fossil fuels
Nuclear energy
Hydroelectric energy
Non-conventional Energy Resources
Wind energy
Bio-fuel
Solar energy
Tidal energy
Hydrogen fuel energy
Geothermal energy
References
Forest Resources
Importance of Forest Resources
Associated Problems of Forests
Deforestation
Causes of Deforestation
Effects of Deforestation
Timber Extraction
Effects of Timber Extraction
Mining
Effects of Mining
References
Mineral Resources
Types of Mineral Resources
Uses of Mineral Resources
Associated problems with Mineral Resources
Environmental problems due to extracting & using Mineral Resources
Water Resources
Use of Water Resources
Over-utilization of surface & ground water
Problems due to overuse of Surface & Ground water
Mineral Resources
Types of Mineral Resources
Uses of Mineral Resources
Associated problems with Mineral Resources
Environmental problems due to extracting & using Mineral Resources
Natural Resources
Renewable Resources
Non-renewable Resources
Difference between Renewable & Non-renewable Resources
Natural Resources & associated problems
Role of individual in conservation of natural resource
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
1. Presented By:-
Machhi Dhruvi Anilkumar
1st Sem. M.Pharm.
Department of Pharmaceutical Quality Assurance
Smt. B. N. B. Swaminarayan Pharmacy College, Salvav-vapi
Topic:- Submission Documents for
regulators DMFs, as CTD & eCTD
Subject Name:- Quality Control & Quality Assurance
Subject Code:- MQA103T
1
3. Drug Master File (DMF)
A Drug Master File (DMF) is a submission to the Food and Drug
Administration (FDA) that may be used to provide confidential detailed
information about facilities, processes, or articles used in the manufacturing,
processing, packaging, and storing of one or more human drugs.
The submission of a DMF is not required by law or FDA regulation.
A DMF is submitted solely at the discretion of the holder.
The information contained in the DMF may be used to support an Investigational New
Drug Application (IND), a New Drug Application (NDA), an Abbreviated New Drug
Application (ANDA), another DMF, an Export Application, or amendments and
supplements to any of these.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 3
4. SUBMISSIONS TO DRUG MASTER FILES:-
Each DMF submission should contain a transmittal letter, administrative information
about the submission, and the specific information to be included in the DMF.
The DMF must be in the English language. Whenever a submission contains
information in another language, an accurate certified English translation must also be
included.
Each page of each copy of the DMF should be dated and consecutively numbered. An
updated table of contents should be included with each submission.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 4
5. Submission to DMF includes
A. Transmittal Letters
1. Original Submissions
2. Amendments
B. Administrative Information
1. Original Submissions
2. Amendments
C. Drug Master File Contents
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 5
6. 2. TRANSMITTAL LETTERS
The following should be included:
2.1 Original Submissions
(a) Identification of submission: Original, the type of DMF & its subject.
(b) Identification of the applications, if known, that the DMF is intended to support,
including the name and address of each sponsor, applicant, or holder, & all relevant
document numbers.
(c) Signature of the holder or the authorized representative.
(d) Typewritten name and title of the signer.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 6
7. 2.2 Amendments
(a) Identification of submission: Amendment, the DMF number, type of DMF, & the
subject of the amendment.
(b) A description of the purpose of submission, e.g., update, revised formula, or revised
process.
(c) Signature of the holder or the authorized representative.
(d)Typewritten name & title of the signer.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 7
8. 3. ADMINISTRATIVE INFORMATION
Administrative information should include the following:
3.1 Original Submissions
(a) Names and addresses of the following:
(i) DMF holder.
(ii) Corporate headquarters.
(iii) Manufacturing/processing facility.
(iv) Contact for FDA correspondence.
(v) Agent(s), if any.
(b) The specific responsibilities of each person listed in any of the categories
(c) Statement of commitment.
A signed statement by the holder certifying that the DMF is current and that the DMF
holder will comply with the statements made in it.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 8
9. 3.2 Amendments
a. Name of DMF holder.
b. DMF number.
c. Name and address for correspondence.
d. Affected section &/or page numbers of the DMF.
e. The name & address of each person whose IND, NDA, ANDA, DMF, or Export
Application relies on the subject of the amendment for support.
f. The number of each IND, NDA, ANDA, DMF, & Export Application that relies on
the subject of the amendment for support, if known.
g. Particular items within the IND, NDA, ANDA, DMF, & Export Application that are
affected, if known.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 9
10. 4. DRUG MASTER FILE CONTENTS
4.1 Types of Drug Master Files
4.1.1 Type I: Manufacturing Site, Facilities, Operating Procedures, & Personnel
4.1.2 Type II: Drug Substance, Drug Substance Intermediate, and Material Used in
Their Preparation, or Drug Product
(i) Drug Substance Intermediates, Drug Substances, and Material Used in Their
Preparation
(ii) Drug Product
4.1.3 Type III: Packaging Material
4.1.4 Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their
Preparation
4.1.5 Type V: FDAAccepted Reference Information
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 10
11. 4. DRUG MASTER FILE CONTENTS
4.2. General Information & Suggestions
4.2.1 Environmental Assessment
4.2.2 Stability
4.2.3 Format, Assembly & Delivery
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 11
12. 4.1 TYPES OF DRUG MASTER FILES
4.1.1 Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel
4.1.2 Type II: Drug Substance, Drug Substance Intermediate, and Material Used in
Their Preparation, or Drug Product
4.1.3 Type III: Packaging Material
4.1.4 Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their
Preparation
4.1.5 Type V: FDAAccepted Reference Information
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 12
13. 4.1.1 TYPE I: MANUFACTURING SITE, FACILITIES,
OPERATING PROCEDURES, & PERSONNEL
It is recommended for a person outside of the United States to assist FDA in
conducting on site inspections of their manufacturing facilities.
The DMF should describe the
- manufacturing site,
- equipment capabilities &
- operational layout.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 13
14. 4.1.2 TYPE II: DRUG SUBSTANCE, DRUG SUBSTANCE
INTERMEDIATE, & MATERIAL USED IN THEIR
PREPARATION, OR DRUG PRODUCT
A Type II DMF should, in general, be limited to a single drug intermediate, drug
substance, drug product, or type of material used in their preparation.
It is further divided in two parts
4.1.2.1 Drug Substance Intermediates, Drug Substances, and Material Used in Their
Preparation
4.1.2.2 Drug Product
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 14
15. 4.1.2.1 DRUG SUBSTANCE INTERMEDIATES, DRUG
SUBSTANCES, & MATERIAL USED IN THEIR PREPARATION
Type II DMF for drug substances and intermediates may be found in the following
guidelines:
Guideline for Submitting Supporting Documentation in Drug Applications for the
Manufacture of Drug Substances.
Guideline for the Format and Content of the Chemistry, Manufacturing, and Controls
Section of an Application.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 15
16. 4.1.2.2 DRUG PRODUCT
When a Type II DMF is submitted for a drug product, the applicant/sponsor should
follow the guidance provided in the following guidelines:
Guideline for the Format and Content of the Chemistry, Manufacturing, & Controls
Section of an Application.
Guideline for Submitting Documentation for the Manufacture of & Controls for Drug
Products
Guideline for Submitting Samples & Analytical Data for Methods Validation
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 16
17. 4.1.3 TYPE III: PACKAGING MATERIAL
Each packaging material should be identified by the intended use, components,
composition, & controls for its release.
The names of the suppliers or fabricators of the components used in preparing the
packaging material & the acceptance specifications should also be given.
Data supporting the acceptability of the packaging material for its intended use should
also be submitted as outlined in the "Guideline for Submitting Documentation for
Packaging for Human Drugs & Biologics."
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 17
18. 4.1.4 TYPE IV: EXCIPIENT, COLORANT, FLAVOR,
ESSENCE, OR MATERIAL USED IN THEIR
PREPARATION
Each additive should be identified and characterized by its method of manufacture, release
specifications, & testing methods.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 18
19. 4.1.5 TYPE V: FDAACCEPTED REFERENCE
INFORMATION
FDA discourages the use of Type V DMF's for miscellaneous information, duplicate
information, or information that should be included in one of the other types of
DMF’s.
If any holder wishes to submit information & supporting data in a DMF that is not
covered by Types I through IV, a holder must first submit a letter of intent to the Drug
Master File Staff. FDA will then contact the holder to discuss the proposed
submission.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 19
20. 4.2 GENERAL INFORMATION &
SUGGESTIONS
4.2.1 Environmental Assessment
4.2.2 Stability
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 20
21. 4.2.1 ENVIRONMENTALASSESSMENT
Type II, Type III, and Type IV DMF's should contain a commitment by the firm that
its facilities will be operated in compliance with applicable environmental laws. If a
completed environmental assessment is needed, see 21 CFR Part 25.
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 21
22. 4.2.2 STABILITY
Stability study design, data, interpretation, & other information should be submitted,
when applicable, as outlined in the “Guideline for Submitting Documentation for the
Stability of Human Drugs & Biologics.”
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 22
23. 5. REFERENCES:-
Drug Master Files: Guideline Center for Drug Evaluation and Research Food and
Drug Administration Department of Health and Human Services, September 1989
(https://www.fda.gov/drugs/guidances-drugs/drug-master-files-guidelines )
4/6/2022
Dhruvi Machhi Smt.BNB.SPC,Salvav-Vapi 23